KeyBanc lowered the firm’s price target on UnitedHealth (UNH) to $400 from $450 and keeps an Overweight rating on the shares. The firm believes the stock has likely overshot to the downside, with current valuation potentially implying an EPS power that embeds less than 0% margins for the company’s MA business. KeyBanc thinks this dislocation is unlikely to sustain over the long term. Additionally, it maintains that the negative issues impacting 2025 are fixable starting in 2026. While patience will be required and uncertainty is elevated, the firm believes the 12-month+ setup from here is attractive, arguing that UnitedHealth is the bellwether MCO, trading at a historically discounted valuation on depressed margins.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- Winners and Losers: Energy Stocks Soared and Healthcare Crashed in May
- ‘Buy Now or Regret Later,’ Says Top Investor About UnitedHealth Stock
- Why Buying the UnitedHealth (UNH) Stock Dip is a Bad Idea
- Options Market Offers Compelling Trading Strategy for UnitedHealth Stock (UNH)
- UnitedHealth (UNH) Sets Sights on Market Comeback After Brutal Quarter
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue